FDA Approves Under-the-Tongue Allergen Tablet to Treat Dust Mite Allergy in Children Ages 12-17

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from ALK to bring you the latest research news. [PRESS RELEASE] U.S. FDA Approves ALK’s ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents – ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age, in addition to adults 18 through 65 years of age – – Nearly 50% of…

Lesen Sie weiter auf: FDA Approves Under-the-Tongue Allergen Tablet to Treat Dust Mite Allergy in Children Ages 12-17
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• 2023 Allergy Capitals™ Report: Where Does Your City Rank?
• Learn How to Better Manage CSU (Webinar)
• Ask the EPA to Strengthen the Soot Pollution Standards
• Darren Riley: Working Toward Equitable Air Quality
• Asthma Medicines Can Affect Your Oral Health
• Asthma and the “Tripledemic” (Flu, COVID-19, and RSV) - Video
• Asthma and Allergy Research Updates – February 2023
• Families Managing Asthma in Four U.S. Cities Receive Products to Help Them Make Their Homes Healthier
• Linda Nozart: Guiding a Community Toward Better Asthma Control
• Recall Alert: Skippack SARS-CoV-2 Antigen Rapid Test Kit